You are about to leave the Clinical Value website now.


AOGIN 2022 – Advancing women’s health: optimising cervical cancer screening in Thailand

Since 2020, Thailand has used HPV DNA tests as a way to optimise primary screening programmes for cervical cancer. The country conducted internal studies on the cost-effectiveness of HPV tests within primary screening and found it to be economical. To increase coverage amongst the unscreened or under-screened population, self-sampling was introduced to address cultural and/or religious barriers and increase convenience for those who had routine healthcare services delayed due to Covid-19.

In this recording from AOGIN 2022, Prof Wichai Termrungruanglert of Chulalongkorn University in Bangkok, Thailand, shares how the Thai healthcare system has responded to the changing needs of the screening population. Watch the recording to find out more.

Prof Wichai Termrungruanglert

Head of Department, Obstetrics and Gynecology, Chulalongkorn University, Thailand

Be the first to receive updates, event opportunities, and thought leadership insights.